Novo Nordisk announces 2030 growth targets at capital markets day in London
1 Sep 21 4:25 AM · 6d ago · 1 article · 1 source · development 1 of 5
The Danish pharmaceutical company outlined a long-term strategy including plans to launch more than five blockbuster drugs by 2030, achieve compound annual revenue growth in line with industry peers through 2030 while maintaining stable operating margins, and expand manufacturing to make oral GLP-1 treatments available to 10 times as many people with obesity. The company also expects its risk-adjusted pipeline to generate more than DKK 150 billion in sales by 2035.
Novo Nordisk Danish pharmaceutical company
Mike Doustdar Novo Nordisk Chief Executive OfficerEli Lilly & Co. Rival pharmaceutical company
The whole story articlesposts the bright band is this development · numbered dots are the others · click one to jump
What was reported 2 claims about this development
-
first by Yahoo Finance, 6d ago · also Quartz, Investing.com News
3 more headlines
- Novo Nordisk stock sinks after 2030 growth plan fails to impress investors Quartz · 6d ago
- Why is Novo Nordisk stock sliding today? Investing.com News · 6d ago
- Why Novo Nordisk Stock Just Crashed Yahoo Finance · 6d ago
-
first by Investing.com News, 6d ago
All 5 developments of Novo Nordisk shares plunge 7% as 2030 growth plan… →
NewswiresMastodonGoogle News